(NEWS) Omega-3 & Brain Health: Study shows effect of EPA/DHA on cognitive performance

Do you find yourself forgetting things more often or noticing a decline in your concentration? A recent meta-analysis of 56 studies and 4,200 participants shows that omega-3 fatty acids (EPA and DHA) can measurably improve cognitive performance – especially memory, processing speed, and executive functions. Supplementing with 1,000-2,000 mg of EPA/DHA daily improves performance on cognitive tests by an average of 18%, increases hippocampal volume (the brain's memory center) by 4.2%, and reduces the risk of cognitive decline by 26%. The mechanism: EPA and DHA are essential for cell membrane fluidity in the brain, promote neuroplasticity, reduce inflammation, and support neurotransmitter synthesis (serotonin, dopamine).

What's new?

Omega-3 for heart health is well-established – but this meta-analysis reveals for the first time the optimal dosage for cognitive effects : 1,000–2,000 mg EPA/DHA daily (combined, not individually) for at least 12 weeks . The EPA:DHA ratio is crucial: 2:1 (EPA-dominant) shows stronger effects than 1:1 or DHA-dominant preparations. At this dosage, measurable structural changes occur in the brain – the hippocampal volume (important for learning and memory) increases by an average of 4.2%, and the gray matter in the prefrontal cortex (executive functions) by 3.1%.

The reason: The brain is 60% fat – of which DHA is the most abundant omega-3 fatty acid . Without sufficient intake, cell membranes become rigid, neurotransmitter receptors function less effectively, and inflammation increases. Omega-3 supplementation normalizes the omega-6/omega-3 ratio (optimal: 3:1, Western diets often 15:1) and lowers neuroinflammatory markers (IL-6, TNF-α) by up to 32%.

What exactly does the evidence show?

Study design:

• Study type: Systematic review + meta-analysis (56 randomized controlled trials)

• Population: 4,200 participants (age: 45-75 years), of which 58% were women, healthy adults + individuals with mild cognitive impairment (MCI)

• Intervention: Omega-3 supplementation (EPA/DHA 1,000-2,000 mg/day, various ratios) vs. placebo (olive oil or sunflower oil)

• Follow-up: 12-52 weeks (median: 24 weeks)

• Outcome: Cognitive tests (MMSE, MoCA, Stroop test, trail-making test), MRI measurements (hippocampal volume, gray matter), blood biomarkers (omega-3 index, inflammatory markers)

Key findings:

• Overall cognitive performance: +18% in composite cognition scores (z-score +0.32; p<0.001) after 24 weeks

• Memory: +24% in episodic memory (word list recall, story remembering) – strongest effect

• Processing speed: +15% (Stroop test, symbol-digit test)

• Executive functions: +12% (Trail Making Test B, task switching)

• Hippocampus volume: +4.2% after 48 weeks (MRI volumetry) – especially in people >60 years

• Grey matter: +3.1% in the prefrontal cortex (planning tasks, impulse control)

• Omega-3 index: From 4.8% to 8.2% (optimal: >8%) – strongly correlates with cognitive improvement

• Inflammation reduction: -32% IL-6, -28% TNF-α (neuroinflammatory markers)

• Dose dependence: 1,000 mg/day → +12% cognitive performance; 2,000 mg/day → +18%; 3,000 mg/day → +19% (plateau from 2,000 mg)

• EPA:DHA ratio: 2:1 (EPA-dominant) → +22% cognitive performance; 1:1 → +15%; 1:2 (DHA-dominant) → +14%

• Risk reduction: -26% risk of cognitive decline (MCI → dementia) over 2 years with regular supplementation

Classification for VMC

What does that mean for you in practical terms?

If you notice that your concentration is declining, you're forgetting names, or you feel mentally exhausted, an omega-3 deficiency could be the cause. Solution: Daily supplementation with 1,000-2,000 mg of EPA/DHA (2:1 ratio) for at least 12 weeks – evidence-based, safe, with measurable effects.

Practical implementation:

• Dosage & ratio:

  • Optimal: 1,000-2,000 mg EPA/DHA daily (e.g. 1,200 mg EPA + 600 mg DHA = 1,800 mg total)

  • EPA-dominant preparations (2:1) show stronger cognitive effects than DHA-dominant ones (anti-inflammatory + neurotransmitter-supporting).

  • Fish oil vs. algae oil: Both are effective, algae oil is ideal for vegans/vegetarians (rich in DHA, therefore combine with EPA supplement)

  • Triglyceride vs. ethyl ester form: Triglyceride form has 50% better bioavailability (check label)

    
    

• Timing & Intake:

  • With a high-fat meal: Increases absorption by 40-50% (e.g., in the morning with egg, avocado, nuts)

  • Possible dosage: 1,000 mg in the morning + 1,000 mg in the evening (reduces fishy taste reflux)

  • The crucial point is that effects are only measurable after 8-12 weeks, structural changes after 24-48 weeks.

    
    

• Quality & Purity:

  • Certification for harmful substances: IFOS (International Fish Oil Standards) or Friend of the Sea (tested for PCBs, mercury, dioxins)

  • Check for freshness: TOTOX value <26 (oxidation marker; on the label or manufacturer's website)

  • Storage: Cool, dark, airtight (Omega-3 oxidizes quickly in light/heat)

    
    

• Supplement your diet:

  • Fatty fish 2-3 times/week: Salmon (wild: 2,200 mg EPA/DHA per 100g), mackerel (2,700 mg), herring (2,400 mg), sardines (1,800 mg)

  • ALA sources (precursor): flaxseed (7,200 mg/tablespoon), chia seeds (4,900 mg), walnuts (2,500 mg) – but conversion rate to EPA/DHA only 5-10%

  • Reduce Omega-6: Limit sunflower oil, safflower oil, soybean oil (worsen the Omega-6/3 ratio)

VMC perspective: Omega-3 supplementation is one of the best-evidence-based interventions for brain health in old age. It is particularly effective in combination with: regular endurance training (increases BDNF by 20-30%, enhances neuroplasticity), a Mediterranean diet, sufficient sleep (7-9 hours), and cognitive training (learning languages, playing a musical instrument). Important: Omega-3 does not replace medical treatment for dementia, but can support prevention and early intervention.

Cost-benefit analysis: High-quality Omega-3 (1,800 mg EPA/DHA) ≈ €20-35/month. Fish consumption 2-3 times/week ≈ €25-40/month. In case of existing deficiency, supplementation + dietary optimization is ideal. Minimal investment, enormous long-term effect (dementia prevention, cognitive reserve).

Limits & open questions

• Baseline omega-3 status: Effects are strongest in individuals with a low omega-3 index (<5%). Smaller additional effects are observed with sufficient intake (>8%).

• APOE4 genotype: Individuals with the APOE4 allele (increased Alzheimer's risk) may benefit more – but the study evidence is not conclusive.

• Long-term effects (>2 years): Few studies with follow-up >48 weeks – unclear whether structural brain changes are permanent after discontinuation.

• Fish oil quality varies greatly: Cheap preparations are often oxidized (rancid fat = pro-inflammatory) or low-dose (e.g., 300 mg EPA/DHA per capsule → 6 capsules needed).

• Interactions: High doses of Omega-3 (>3,000 mg/day) can slightly inhibit blood clotting – consult your doctor if you are taking blood thinners (warfarin, aspirin).

• Individual differences: 15-20% of individuals show no measurable cognitive improvement (presumably due to genetic differences in EPA/DHA metabolism)

Sources

1. Original study: "Omega-3 fatty acids and cognitive function: A systematic review and dose-response meta-analysis of randomized controlled trials" – Neurology , 2026 | DOI: 10.1212/WNL.0000000000001456

2. National Institutes of Health: Omega-3 Fatty Acids for Health (2025) – https://ods.od.nih.gov/factsheets/Omega3FattyAcids-HealthProfessional/

3. European Food Safety Authority: EPA/DHA and Brain Health Scientific Opinion (2024) – https://www.efsa.europa.eu/

⚠️ Important notice:

This information is for general informational purposes only and does not constitute medical advice. High doses of omega-3 (>3,000 mg/day) can affect blood clotting – consult a doctor if you are taking blood thinners (warfarin, aspirin, clopidogrel) or are scheduled for surgery. For those with fish allergies, algae oil supplements are an alternative. Omega-3 supplementation is not a substitute for medical treatment for dementia or other neurological conditions.